Navigation Links
BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
Date:8/13/2008

MOUNTAIN VIEW, California, August 13 /PRNewswire-FirstCall/ -- BN ImmunoTherapeutics, Inc. has entered into a scientific partnership with the National Cancer Institute (NCI) in the United States. Under the Cooperative Research and Development Agreement (CRADA) the NCI and BN ImmunoTherapeutics will jointly develop new immunotherapies for the treatment of prostate cancer. Under the CRADA, BN ImmunoTherapeutics has rights to exclusively license intellectual property that results from this collaboration.

The company plans to in the future explore opportunities for extending this collaboration to further develop its cancer projects. By combining the company's expertise within cancer vaccine development with one of the world's leading centres of excellence within cancer research, the company is confident that this collaboration will result in new and innovative solutions to a disease area with high unmet medical needs as well as expand and accelerate the company's cancer activities.

Through the collaboration and a license agreement with the United States Public Health Service, the company has obtained rights to intellectual property rights covering a prostate cancer vaccine product candidate in late phase II clinical development. Data from key clinical studies with this vaccine candidate are currently being evaluated. Later in 2008 the company will inform the market about how this development project will have a future in the pipeline of the company.

About the NCI

The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH) and is the United States federal government's leading cancer research organization.

- The National Cancer Institute (NCI) has played an active role in the development of drugs for cancer treatment for over 50 years. This is reflected in the fact that approximately one half of the chemotherapeutic drugs currently used by oncologists for cancer treatment were discovered and/or developed
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 A novel robotic system that ... is currently being tested as part of a biomedical ... Boston with the aim of determining if the robot, ... cancer biopsies faster, more accurate, less costly, and less ... the potential to deliver prostate cancer therapies with greater ...
(Date:9/18/2014)... 2014 Research and Markets has ... Stem Cell Industry Report, 2014-2017" report to their ... cells that can differentiate into specialized cells and can ... cell therapy can be applied to treatment of cardiovascular ... system diseases, damage or lesion of liver, kidney and ...
(Date:9/18/2014)... LOUIS , Sept. 18, 2014  U.S. biotech ... by signing an exclusive license for technology developed by ... control gene expression in plants, including for applications in ... The technology was developed under the ... officer at Kultevat and former president of the Danforth ...
(Date:9/18/2014)... 18, 2014   Sigma-Aldrich Corporation (Nasdaq: ... entered into a new gene editing partnership with ... Core. Under the partnership, Sigma-Aldrich will provide the ... consultation, and dedicated gene editing bioinformaticians. ... research at the U-M Medical School. One initiative ...
Breaking Biology Technology:Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Kultevat obtains license of gene switch technology 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... perfect example of the wonders of nanotechnology, in which common ... new and exciting possibilities. , Graphene ... graphitic carbon, which is used to make the pigment that ... to a one-atom-thick sheet. Graphene is among the strongest materials ...
... will result in over $80 million reduction in 2009 ... Pharmaceuticals,Inc. (Nasdaq: AMLN ) today announced a corporate ... 25 percent, or 340,employees, and reduce anticipated 2009 cash ... reduction are part of the,Company,s business plan to be ...
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) announced today financial ... 30, 2008., Third Quarter and Nine Months Financial ... months ended Sept. 30, 2008, was,$3.8 million and $12.2 ... in 2007. Revenue in the third quarter and nine,months ...
Cached Biology Technology:Researchers discover method for mass production of nanomaterial graphene 2Researchers discover method for mass production of nanomaterial graphene 3Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction 2Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction 3Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 2Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 3Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 4Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 5Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 6
(Date:9/18/2014)... developed a unique method to use microbes buried in ... , The first microbe-powered, self-sustaining wastewater treatment system ... clean up waste from large farming operations and rural ... Haluk Beyenal and graduate student Timothy Ewing in the ... in the online edition of Journal of Power ...
(Date:9/18/2014)... can operate inside the bore of an MRI scanner ... research partnership program at Brigham and Women,s Hospital in ... in conjunction with real-time MRI images, can make prostate ... discomforting for the patient. The novel system also has ... precision. , Developed by a team of robotics engineers ...
(Date:9/18/2014)... acquire and creatively manipulate spoken language is unique to ... 6 million years of human evolution to make this ... candidate gene we now have," says Wolfgang Enard, Professor ... efforts to understand the molecular biological basis of language ... results of his latest study, undertaken in collaboration with ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... UC Davis cancer researchers have found that older men ... regular CT scans over lymph node removal are at ... last week in the journal Cancer, indicate that physicians ... when discussing treatment options with their patients. ...
... University of Washington physicists are detecting radioactivity from ... a mammoth March 11 earthquake, but the levels are ... health. On March 16, the scientists began testing ... Building on the UW campus, looking for evidence of ...
... is available in German . , Innovations relating ... presented by KIT at the 2011 Hannover Messe from April ... KIT will present a hybrid Porsche racing car, developments in ... InnoEnergy for a European energy supply system, and the Energy ...
Cached Biology News:Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 2Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 3Physicists detect low-level radioactivity from Japan arriving in Seattle 2Physicists detect low-level radioactivity from Japan arriving in Seattle 3KIT presents innovations at the 2011 Hannover Messe 2KIT presents innovations at the 2011 Hannover Messe 3KIT presents innovations at the 2011 Hannover Messe 4KIT presents innovations at the 2011 Hannover Messe 5
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... System is used in conjunction ... PCR of problematic and/or GC-rich ... Solution with 10X PCRX Amplification ... broader magnesium concentration broader annealing ...
MAGP-2 (C-19)...
Biology Products: